96 related articles for article (PubMed ID: 7060314)
1. Clinical kinetics of 1, 4-dihydroxy-5,8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino ]-9, 10-anthracenedione.
Savaraj N; Lu K; Valdivieso M; Burgess M; Umsawasdi T; Benjamin RS; Loo TL
Clin Pharmacol Ther; 1982 Mar; 31(3):312-6. PubMed ID: 7060314
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog.
Lu K; Savaraj N; Loo TL
Cancer Chemother Pharmacol; 1984; 13(1):63-6. PubMed ID: 6733844
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
Von Hoff DD; Pollard E; Kuhn J; Murray E; Coltman CA
Cancer Res; 1980 May; 40(5):1516-8. PubMed ID: 7370989
[TBL] [Abstract][Full Text] [Related]
4. Clinical analysis for the anti-neoplastic agent 1,4-dihydroxy-5,8-bis((2-[(2-hydroxyethyl)amino]ethyl)-amino)9,10-anthracenedio ne dihydrochloride (NSC 301739) in plasma. Application of temperature control to provide selectivity in paired-ion high-performance liquid chromatography.
Reynolds DL; Sternson LA; Repta AJ
J Chromatogr; 1981 Feb; 222(2):225-40. PubMed ID: 7251740
[TBL] [Abstract][Full Text] [Related]
5. Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione, with nucleic acids.
Kapuscinski J; Darzynkiewicz Z; Traganos F; Melamed MR
Biochem Pharmacol; 1981 Feb; 30(3):231-40. PubMed ID: 7225141
[No Abstract] [Full Text] [Related]
6. [Mitoxantrone HCl (1,4-dihydroxy-4, 8-bis[[2-(hydroxyethyl)-amino-ethyl)]amino 9,10-anthracenedione dihydrochloride (NSC 301739) - a new cytostatic].
Hagenberg L; Loynds P; Nagel GA
Onkologie; 1980 Dec; 3(6):322-8. PubMed ID: 6784060
[No Abstract] [Full Text] [Related]
7. Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
Taylor SA; Tranum BT; Von Hoff DD; Costanzi JJ
Invest New Drugs; 1985; 3(1):67-9. PubMed ID: 3988458
[TBL] [Abstract][Full Text] [Related]
8. Competitive fluorescence polarization study of the binding of 1,4-dihydroxy-5,8-bis[(2-[(2-hydroxyethyl) amino] ethyl]amino] 9-10-anthracenedione to DNA.
Richardson CL; Roboz J; Holland JF
Res Commun Chem Pathol Pharmacol; 1980 Mar; 27(3):497-506. PubMed ID: 7384639
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug.
Alberts DS; Griffith KS; Goodman GE; Herman TS; Murray E
Cancer Chemother Pharmacol; 1980; 5(1):11-5. PubMed ID: 7460190
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the pharmacokinetics of bisantrene (NSC-337766).
Kuhn JG; Ludden TM; Myers JW; Von Hoff DD
Invest New Drugs; 1983; 1(3):253-7. PubMed ID: 6678875
[TBL] [Abstract][Full Text] [Related]
11. Comparative structure-genotoxicity study of three aminoanthraquinone drugs and doxorubicin.
Au WW; Butler MA; Matney TS; Loo TL
Cancer Res; 1981 Feb; 41(2):376-9. PubMed ID: 7448780
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride.
Lu K; Savaraj N; Yap BS; Feun LG; Umsawasdi T; Loo TL
Cancer Chemother Pharmacol; 1986; 16(2):156-9. PubMed ID: 3948302
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog.
Lu K; Loo TL
Cancer Res; 1980 May; 40(5):1427-30. PubMed ID: 7370981
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and metabolism of mitoxantrone in man.
Ehninger G; Proksch B; Heinzel G; Schiller E; Weible KH; Woodward DL
Invest New Drugs; 1985; 3(2):109-16. PubMed ID: 4019115
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of mitoxantrone performed by a NONMEM method.
Launay MC; Iliadis A; Richard B
J Pharm Sci; 1989 Oct; 78(10):877-80. PubMed ID: 2600798
[TBL] [Abstract][Full Text] [Related]
16. Isolation and identification of a new impurity in mitoxantrone hydrochloride.
Haiyan L
Pharmazie; 2009 Jun; 64(6):376-9. PubMed ID: 19618673
[TBL] [Abstract][Full Text] [Related]
17. Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl hydrazone) dihydrochloride.
Powis G
J Chromatogr; 1981 Dec; 226(2):514-20. PubMed ID: 7320182
[No Abstract] [Full Text] [Related]
18. Plasma kinetics of mitoxantrone in leukemic patients.
Hulhoven R; Dumont E; Harvengt C
Med Oncol Tumor Pharmacother; 1984; 1(3):201-4. PubMed ID: 6544900
[TBL] [Abstract][Full Text] [Related]
19. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.
Wallace RE; Murdock KC; Angier RB; Durr FE
Cancer Res; 1979 May; 39(5):1570-4. PubMed ID: 427798
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
